Pharmaceuticals News

The pharmaceuticals news email from Wiser has been specifically designed for anyone with an interest in the industry. This includes medical practitioners, investors and those involved in research and development. By its very nature, the pharmaceutical industry is subject to constant change. It is a research-driven industry with companies spending much of their revenues developing new medicines and vaccines. As a result patients are able to get new and more effective treatments. This is helping to increase the life expectancy of individuals in most countries. But there are challenges. The costs of the research and development can be large which puts up the price of drugs, while governments and the medical industry argue to try to keep prices as low as possible. The industry also faces challenges from alternatives, both legal (through generic drugs) and illegal (through black market economies). To follow the latest developments in this industry you should sign up for the pharmaceuticals news email from Wiser. It is the best way to find must-read articles on the topic from around the web.

Recent Pharmaceuticals News Coverage
 
Your Weekly Recommendations Tuesday, September 19, 2017
 
Recommended for you
Zai Lab Updates Proposed $100 Million U.S. IPO Terms
Seeking Alpha • Donovan Jones
Rising Demand for Vitamin E to Boost the Propionic Acid Market: Technavio
BusinessWire
CardioBrief: What If PCI Is Just a Sham?
MedPage Today • Larry Husten
Company Update (NYSE:TEVA): Teva Pharmaceutical Industries Ltd (ADR) Joins Forces with Nuvelution Pharma to Develop AUSTEDO Tablets in Tourette Syndrome in U.S.
Smarter Analyst • Corey Williams
​Three Healthy Ideas for Value Investors
Equities.com • Moneyshow
Acceleron Showcases Vision and Strategy at 2017 R&D Day
BusinessWire
CardioMEMS PA-Pressure Sensor: Prowess, Cautions in HF Management
theHeart.org
BRIEF-Teva and Nuvelution Pharma partner to accelerate development of Austedo tablets for use in Tourette Syndrome in the united states
Reuters • Reuters Staff
BRIEF-Mimedx files with FDA to initiate co's investigational new drug Phase 2 clinical trial for Osteoarthritis of Knee
Reuters • Reuters Staff
Partnerships Pave the Road to Effective Alzheimer’s Drug Treatment
R&D Magazine All • Lpanjwani
 
Recommended for You
Health Finance, Pharmaceuticals
Zai Lab Updates Proposed $100 Million U.S. IPO Terms
Seeking AlphaDonovan Jones
Summary China-based Zai Lab has proposed terms for its U.S. IPO. The firm is pursuing a promising strategy of in-licensing already approved western drugs for a range of large market indications within China. I favor this lower risk approach for investors who...
Share
GlaxoSmithKline plc, Healthy Living
Rising Demand for Vitamin E to Boost the Propionic Acid Market: Technavio
BusinessWire
LONDON--(BUSINESS WIRE)--Technavio’s latest market research report on the global propionic acid marketprovides an analysis of the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact...
Share
Health Care Industry, Pharmaceuticals
CardioBrief: What If PCI Is Just a Sham?
MedPage TodayLarry Husten
What if percutaneous coronary intervention (PCI) for stable ischemic heart disease is just a big lie? That is, what if it's no better than a sham procedure? This may seem like a crazy proposition, but there's at least an outside chance that...
Share
Pharmaceuticals
Company Update (NYSE:TEVA): Teva Pharmaceutical Industries Ltd (ADR) Joins Forces with Nuvelution Pharma to Develop AUSTEDO Tablets in Tourette Syndrome in U.S.
Smarter AnalystCorey Williams
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Nuvelution Pharma are officially in collaboration for the development of AUSTEDO (deutetrabenazine) tablets, designed to treat Tourette syndrome (TS) tics in pediatric patients in the United States. By partnering with Nuvelution, Teva can get the...
Share
Barack Obama, Finance
​Three Healthy Ideas for Value Investors
Equities.comMoneyshow
Image via Mike Mozart/Flickr CC John Buckingham is a leading proponent of value investing, focused on a widely diversified portfolio for long-term investors. Three of the latest buys in his The Prudent Speculator come from various sectors of the healthcare market—a drugstore...
Share
Epidemiology, Financial Regulatory Bodies
Acceleron Showcases Vision and Strategy at 2017 R&D Day
BusinessWire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, hosted its Research and Development (R&D) Day in New York City today. The Company discussed clinical development plans...
Share
Cardiovascular Disease, Hazardous Waste
CardioMEMS PA-Pressure Sensor: Prowess, Cautions in HF Management
theHeart.org
The implanted pulmonary-artery-pressure monitor's postmarket registry seem to indicate efficacy at least as good as in the pivotal clinical trial; adverse events reported to MAUDE provide perspective. Medscape Medical News
Share
Finance, Investment Industry
BRIEF-Teva and Nuvelution Pharma partner to accelerate development of Austedo tablets for use in Tourette Syndrome in the united states
ReutersReuters Staff
Sept 19 () - Teva Pharmaceutical Industries Ltd * Teva and Nuvelution Pharma partner to accelerate development of austedo® (deutetrabenazine) tablets for use in tourette syndrome in the united states * Teva Pharmaceutical Industries Ltd - upon fda approval of austedo® in...
Share
Pharmaceuticals
BRIEF-Mimedx files with FDA to initiate co's investigational new drug Phase 2 clinical trial for Osteoarthritis of Knee
ReutersReuters Staff
Sept 19 () - Mimedx Group Inc * Mimedx files with the FDA to initiate the company’s investigational new drug phase 2 clinical trial for Osteoarthritis of the knee * Mimedx group inc - ‍company expects patient enrollment to commence by end...
Share
Neuroscience, Pharmaceuticals
Partnerships Pave the Road to Effective Alzheimer’s Drug Treatment
R&D Magazine AllLpanjwani
Advancements in treatment for heart disease, stroke and cancer can be traced back to the use of imaging technologies that enable doctors and researchers to visualize the impact and progression of these diseases inside the body. Just a decade ago, we had...
Share